Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The Korea Drug Development Fund (KDDF), through its investment and support of the biopharma sector, translates cutting-edge science into patient benefits and market opportunities.
LR 09, a metabolic immune-checkpoint inhibitor that can initiate graft-versus-leukemia effect in relapsed allogeneic stem-cell transplant (SCT) patients, could become the new standard of care for leukemia.
Ellipses Pharma’s KOL-enabled cloud-based platform is crowdsourcing expert insight from oncologists worldwide to create tailored opportunities for developing drug candidates.
With a lead candidate harnessing antibody-driven cytotoxic mechanisms to drive tumor cell death, Byondis is developing a pipeline of candidates targeting oncology by combining its unrivaled expertise in linker-drug technology, antibody–drug conjugation, targeted cytotoxic therapy and the development of monoclonal antibodies.
Affivant Sciences is developing tetravalent, bispecific antibodies that can recruit multiple innate immune-cell types to attack a range of challenging cancers.
Strike Pharma has developed new affinity-based linkers for optimized delivery of tumor-specific immunogenic peptides to immune cells, creating more efficacious personalized immunotherapies with fewer side effects.
Eterna Therapeutics is using state-of-the-art messenger RNA (mRNA) technology to develop cell and gene therapies for cancer and a wide range of other indications.
The precision medicine services company Oncolines B.V. is accelerating cancer drug development by identifying drug response biomarkers in over 200 genetically characterized cancer cell lines.
By combining molecular science and artificial intelligence with years of experience and a world-leading database, Caris Life Sciences aims to revolutionize cancer care and deliver on the promise of precision oncology medicine in partnership with biopharma and industry innovators.
CalciMedica, a clinical-stage biopharma company, is developing potentially first-in-class small molecules to combat excessive intracellular calcium levels that drive pathological processes in inflammatory diseases and acute injury, including COVID-19.
As a government funder, the Korea Drug Development Fund (KDDF) invests in promising selected compounds by taking them through assessment and translating them into cutting-edge science for patient benefits and market opportunities.
The city of Phoenix hosts a thriving life-sciences ecosystem that fosters collaboration among industry, education, research and community partners to transform discoveries into health.
City of Phoenix Community and Economic Development Department
Metastatic cancer remains one of oncology’s most stubborn problems. MetasTx is developing a first-in-class small-molecule therapy against a unique target that inhibits cancer’s ability to metastasize.
Enterome is using its unique Mimicry approach coupled with the power of partnering to harness the potential of the gut’s natural tolerance pathway to address allergies and autoimmune diseases.
